Skip to main content
Psych Congress  
2017

Tardive Dyskinesia Among Patients Using Antipsychotic Medications in Customary Clinical Care in the United States

Authors  
Anita Loughlin, PhD; Nancy Lin, ScD; Victor Abler, DO; Benjamin Carroll, PharmD
Sponsor  
Teva Pharmaceutical Industries

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Objective: To characterize clinical characteristics of patients with TD.

Methods: This retrospective cohort study included patients who received an antipsychotic prescription (1/1/2011-12/31/2015) from the Optum Electronic Health Record database. Patients were identified based on the presence of a mention of TD in the free-text clinical notes as extracted via natural-language processing, which was likely to represent a clinical diagnosis of TD.

Results: A total of 164,417 patients were identified as having prescriptions for antipsychotics and ≥1 medical visit or hospitalization 12-24 months before the index date. TD prevalence among antipsychotic users was 0.8%, representing 530 prior TD patients (with a TD mention during the 12 months before the index date [baseline]) and 784 new TD patients (with first mention during follow-up). ≥50% of prior and new TD patients had a recorded antipsychotic prescription during the baseline period (prevalent antipsychotic users). >75% of the TD population received an atypical antipsychotic prescription. ~50% of TD patients had evidence of an anxiety/mood disorder. Percentages of patients with schizophrenia and schizophrenia_like disorders were much higher in the TD population than in all patients receiving antipsychotics. Obesity (~70%), diabetes (~30%), and dyslipidemia (~45%) were common comorbidities in the TD population.

Conclusions: TD patients generally had a high comorbidity burden, and more than half were prevalent antipsychotic users. Although most TD patients received atypical antipsychotics in clinical practice, the burden of TD remained high.

Back to Top